Reasons why:1) Leukemia and related blood disorders is a huge field that will continue to grow with the aging population.2)Just as a veteran athlete adds invisible value to a young team Ceplene can strengthen or augment many companies' existing therapies.3) EpiCept can sweeten the deal by adding Canada and U S rights to European rights.4) If Ceplene geta approved in Canada and the U S, sales will be hedged in at least four different currencies. Drug companies don't like sales concentrated in one currency.
If idis-sales are going ok. They could start building their own organization to sell ceplene. Epicept could very soon be cash-flow positive from the idis sales (end of q1 realistically).
The correct figure is 9 month: My first post was...14-Feb-09 10:35 am.Read some Hippocrates.
Some here on the forum seems to have had a small stroke, take a week off and take it easy, and don´t forget to have your legs high up, so your brain get some oxygen!!Have a nice week::))Epicept, very strong buy
In your opinion it is, 14 months later and the paint is still continuing to dry on the wall. NOTHING
<In your opinion it is, 14 months later and the paint is still continuing to dry on the wall. NOTHING>If you invest in small biotechs you can't have a short time horizon. Case in point Dendreon:3/07 $3.65 NOTHING4/07 $19.39 SOMETHING3/09 $2.61 NOTHING10/09 29.51 SOMETHINGHINT: You buy at the NOTHING price(currently EPCT) and sell at the SOMETHING price (EPCT in 2010 and 2011).